We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Microsoft, BP, Zoetis, Lululemon Athletica and Weyerhaeuser
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 15, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , BP p.l.c. (BP - Free Report) , Zoetis Inc. (ZTS - Free Report) , Lululemon Athletica Inc. (LULU - Free Report) and Weyerhaeuser Co. (WY - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Microsoft, BP and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., BP p.l.c and Zoetis Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Microsoft shares largely tracked the Zacks Tech sector this year, but the stock hasn't looked back since the very strong Q1 earnings release on April 25th. As a result, Microsoft shares are now up +28.4% this year vs. +22% for the Zacks Tech sector and the +8.6% gain for the S&P 500 index.
The company is benefiting from strong Intelligent Cloud and Productivity and Business Processes revenues. Intelligent Cloud revenues were driven by growth in Azure and other cloud services. Productivity and Business Processes revenues increased due to strong adoption of Office 365 Commercial solutions. Microsoft is also seen as having a better offering on the artificial intelligence (AI) front than rival Alphabet.
Continued momentum in the small and medium businesses and frontline worker offerings, as well as gain in revenue per user drove top-line growth. However, More Personal Computing revenues decreased due to weak Windows and Devices businesses.
Steady performance in Talent Solutions aided LinkedIn revenues. However, declining gaming revenues has been a headwind. Increasing spend on Azure enhancements amid stiff competition in the cloud space remains a concern.
Shares of BP have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+24.4% vs. +10.2%). The company has a strong portfolio of upstream projects, backing impressive production growth. The company boasted that the target of adding a net production of 900 thousand barrels of oil equivalent per day by 2021 from key projects was met successfully.
BP expects $2-$3 billion of divestment and other proceeds in 2023. Before reporting its June-quarter results, the integrated energy major is willing to complete an additional $1.75 billion in share buy-backs. Also, BP reported better-than-expected first-quarter earnings resulting from an increase in oil-equivalent production volumes.
However, the energy giant's balance sheet is considerably more levered than most peers, limiting its financial flexibility. Also, increasing exploration expenses have been affecting the company's income. As such, the stock warrants a cautious stance.
Zoetis shares have outperformed the Zacks Medical - Drugs industry over the past year (+12.9% vs. -1.8%). The company's innovative portfolio of pet care parasiticides, including Simparica Trio and key dermatology products maintain momentum for the company.
The strong uptake of Librela and Solensia in Europe, its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats, is encouraging. The launch of innovative products bolstered the portfolio and should fuel growth.
However, Zoetis had earlier faced supply challenges which impacted demand. Although the constraints have eased out, a similar situation will impact growth. Stiff competition from animal health business wings of Merck and Bayer remains a woe.
Other noteworthy reports we are featuring today include Lululemon Athletica Inc. and Weyerhaeuser Co..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Microsoft, BP, Zoetis, Lululemon Athletica and Weyerhaeuser
For Immediate Release
Chicago, IL – May 15, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , BP p.l.c. (BP - Free Report) , Zoetis Inc. (ZTS - Free Report) , Lululemon Athletica Inc. (LULU - Free Report) and Weyerhaeuser Co. (WY - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Microsoft, BP and Zoetis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., BP p.l.c and Zoetis Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Microsoft shares largely tracked the Zacks Tech sector this year, but the stock hasn't looked back since the very strong Q1 earnings release on April 25th. As a result, Microsoft shares are now up +28.4% this year vs. +22% for the Zacks Tech sector and the +8.6% gain for the S&P 500 index.
The company is benefiting from strong Intelligent Cloud and Productivity and Business Processes revenues. Intelligent Cloud revenues were driven by growth in Azure and other cloud services. Productivity and Business Processes revenues increased due to strong adoption of Office 365 Commercial solutions. Microsoft is also seen as having a better offering on the artificial intelligence (AI) front than rival Alphabet.
Continued momentum in the small and medium businesses and frontline worker offerings, as well as gain in revenue per user drove top-line growth. However, More Personal Computing revenues decreased due to weak Windows and Devices businesses.
Steady performance in Talent Solutions aided LinkedIn revenues. However, declining gaming revenues has been a headwind. Increasing spend on Azure enhancements amid stiff competition in the cloud space remains a concern.
(You can read the full research report on Microsoft here >>>)
Shares of BP have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+24.4% vs. +10.2%). The company has a strong portfolio of upstream projects, backing impressive production growth. The company boasted that the target of adding a net production of 900 thousand barrels of oil equivalent per day by 2021 from key projects was met successfully.
BP expects $2-$3 billion of divestment and other proceeds in 2023. Before reporting its June-quarter results, the integrated energy major is willing to complete an additional $1.75 billion in share buy-backs. Also, BP reported better-than-expected first-quarter earnings resulting from an increase in oil-equivalent production volumes.
However, the energy giant's balance sheet is considerably more levered than most peers, limiting its financial flexibility. Also, increasing exploration expenses have been affecting the company's income. As such, the stock warrants a cautious stance.
(You can read the full research report on BP here >>>)
Zoetis shares have outperformed the Zacks Medical - Drugs industry over the past year (+12.9% vs. -1.8%). The company's innovative portfolio of pet care parasiticides, including Simparica Trio and key dermatology products maintain momentum for the company.
The strong uptake of Librela and Solensia in Europe, its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats, is encouraging. The launch of innovative products bolstered the portfolio and should fuel growth.
However, Zoetis had earlier faced supply challenges which impacted demand. Although the constraints have eased out, a similar situation will impact growth. Stiff competition from animal health business wings of Merck and Bayer remains a woe.
(You can read the full research report on Zoetis here >>>)
Other noteworthy reports we are featuring today include Lululemon Athletica Inc. and Weyerhaeuser Co..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.